Center-Authored Papers

Filters: Author is Cortes, Jorge  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
2009
Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E et al..  2009.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25):4204-10. Abstract
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F et al..  2009.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(35):6041-51. Abstract
Kantarjian H, Cortes J, Kim D-W, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury JH, Khoroshko N et al..  2009.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.. Blood. 113(25):6322-9. Abstract
2010
Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP et al..  2010.  Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(4):543-7. Abstract
2011
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G et al..  2011.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.. Blood. 117(4):1141-5. Abstract
2012
Cortes J, Radich J, Mauro MJ.  2012.  Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.. Clinical advances in hematology & oncology : H&O. 10(10 Suppl 19):1-16. Abstract
Ballen KK, Woolfrey AE, Zhu X, Woo Ahn K, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL et al..  2012.  Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
2013
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M et al..  2013.  The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.. Frontiers in oncology. 3:218. Abstract
2014
Sabloff M, Sobecks RM, Woo Ahn K, Zhu X, DeLima M, Brown JR, Inamoto Y, Holland KH, Aljurf MD, Laughlin MJ et al..  2014.  Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia? Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20(3):421-4. Abstract
Acute Disease
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Adolescent
Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W et al..  2009.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(4):504-10. Abstract
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Kantarjian H, Cortes J, Kim D-W, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury JH, Khoroshko N et al..  2009.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.. Blood. 113(25):6322-9. Abstract
Adult
Kantarjian H, Cortes J, Kim D-W, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury JH, Khoroshko N et al..  2009.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.. Blood. 113(25):6322-9. Abstract
Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W et al..  2009.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(4):504-10. Abstract
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP et al..  2010.  Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(4):543-7. Abstract
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G et al..  2011.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.. Blood. 117(4):1141-5. Abstract
Aged
Kantarjian H, Cortes J, Kim D-W, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury JH, Khoroshko N et al..  2009.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.. Blood. 113(25):6322-9. Abstract
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP et al..  2010.  Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(4):543-7. Abstract
Tsimberidou A-M, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ et al..  2008.  The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(3):721-30. Abstract